David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$345M |
| 2 |
Biogen
BIIB
|
+$281M |
| 3 |
Bausch Health
BHC
|
+$244M |
| 4 |
SPDR Gold Trust
GLD
|
+$238M |
| 5 |
Coca-Cola
KO
|
+$206M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LyondellBasell Industries
LYB
|
+$397M |
| 2 |
AGN
Allergan Inc
AGN
|
+$374M |
| 3 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$347M |
| 4 |
Microsoft
MSFT
|
+$265M |
| 5 |
IBM
IBM
|
+$251M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 10.34% |
| 2 | Technology | 9.79% |
| 3 | Consumer Discretionary | 9.73% |
| 4 | Healthcare | 8.68% |
| 5 | Financials | 8.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Vanguard Real Estate ETF
VNQ
$39.1B
| $42.7M | 0.07% |
508,000
+165,500
| +48% | +$14.1M |
|
352
CALL
Intuitive Surgical
ISRG
$134B
| $42.7M | 0.07% |
760,500
-594,900
| -44% | -$33.7M |
|
353
Masco
MAS
$14.5B
| $42.5M | 0.07% |
1,812,519
-500,972
| -22% | -$11.4M |
|
|
HUB.B
354
DELISTED
HUBBELL INC CL-B
HUB.B
| $42.4M | 0.07% |
387,172
+228,999
| +145% | +$25.1M |
|
355
CDW
CDW
$17.2B
| $42.1M | 0.06% |
1,131,519
+83,835
| +8% | +$3.05M |
|
356
PUT
Union Pacific
UNP
$183B
| $41.8M | 0.06% |
386,300
-536,600
| -58% | -$63M |
|
357
O-I Glass
OI
$1.1B
| $41.7M | 0.06% |
1,788,077
+684,972
| +62% | +$16.8M |
|
358
Applied Materials
AMAT
$391B
| $41.6M | 0.06% |
1,844,508
+2,515
| +0.1% | +$60.3K |
|
|
HES
359
DELISTED
Hess
HES
| $41.6M | 0.06% |
612,855
+356,188
| +139% | +$25.4M |
|
360
Regeneron Pharmaceuticals
REGN
$85.9B
| $41.4M | 0.06% |
91,753
-17,187
| -16% | -$7.28M |
|
|
IPG
361
DELISTED
Interpublic Group of Companies
IPG
| $41.3M | 0.06% |
1,868,706
+20,645
| +1% | +$438K |
|
362
Thermo Fisher Scientific
TMO
$233B
| $41.3M | 0.06% |
307,260
-287,531
| -48% | -$37.1M |
|
363
Patterson-UTI
PTEN
$4.71B
| $41.2M | 0.06% |
2,193,145
+819,484
| +60% | +$14.1M |
|
364
Check Point Software Technologies
CHKP
$13.3B
| $40.8M | 0.06% |
498,287
+165,777
| +50% | +$13.4M |
|
|
SUNE
365
DELISTED
SUNEDISON, INC COM
SUNE
| $40.8M | 0.06% |
1,699,870
-2,285,082
| -57% | -$49.1M |
|
|
HZNP
366
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $40.4M | 0.06% |
1,557,023
+149,719
| +11% | +$2.74M |
|
|
NLSN
367
DELISTED
Nielsen Holdings plc
NLSN
| $40.3M | 0.06% |
904,190
-435,229
| -32% | -$19.1M |
|
368
PUT
BP
BP
$115B
| $40.3M | 0.06% |
1,241,132
+168,369
| +16% | +$5.51M |
|
369
Coca-Cola Europacific Partners
CCEP
$47.7B
| $40.1M | 0.06% |
906,697
+81,003
| +10% | +$3.54M |
|
|
MRC
370
DELISTED
MRC Global
MRC
| $39.9M | 0.06% |
3,369,986
-594,272
| -15% | -$7.43M |
|
371
Sensata Technologies
ST
$6.23B
| $39.2M | 0.06% |
682,798
+12,125
| +2% | +$645K |
|
|
SPWR
372
DELISTED
SunPower Corporation Common Stock
SPWR
| $39.1M | 0.06% |
1,908,869
-713,143
| -27% | -$13.5M |
|
373
Trip.com Group
TCOM
$29B
| $38.9M | 0.06% |
1,326,948
+1,028,894
| +345% | +$24.8M |
|
|
DYN
374
DELISTED
Dynegy, Inc.
DYN
| $38.9M | 0.06% |
1,236,534
+205,910
| +20% | +$5.88M |
|
375
PUT
Visa
V
$693B
| $38.6M | 0.06% |
590,800
-1,505,600
| -72% | -$99.6M |
|
Similar funds
David Shaw's Q1 2015 Portfolio in Review
As of Q1 2015, David Shaw held 4,408 positions worth $65.3B, down 16% from $77.8B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
David Shaw withdrew a net $15B in Q1 2015, closing 828 positions and reducing 1,784 holdings. Its most notable exit was Allergan Inc, an estimated $374M position sold in full.
By sector, the portfolio is most concentrated in Energy at 10% of assets, up from 8.6% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, David Shaw opened a new position in SPDR Gold Trust worth $231M.
- David Shaw's largest Q1 2015 buy was SPDR Gold Trust: 2,033,000 shares worth $231M.
- David Shaw added most to State Street SPDR S&P 500 ETF Trust in Q1 2015, an estimated $345M increase.
- David Shaw's biggest Q1 2015 reduction was LyondellBasell Industries, cutting an estimated $397M.
- David Shaw fully exited Allergan Inc in Q1 2015, selling an estimated $374M.
- David Shaw's ten largest holdings make up 11% of its $65.3B portfolio in Q1 2015.
- David Shaw opened 448 new positions and closed 828 in Q1 2015.
- David Shaw's portfolio value fell 16% quarter-over-quarter to $65.3B.
Based on D.E. Shaw & Co's 13F filing for Q1 2015, filed 15 May 2015.